We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+44.61%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$502M
AUM Growth
-$46.6M
Cap. Flow
-$131M
Cap. Flow %
-26.01%
Top 10 Hldgs %
39.38%
Holding
180
New
41
Increased
13
Reduced
50
Closed
76

Top Buys

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$12.2M
2
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$10.6M
3
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$7.73M
4
SAGE
Sage Therapeutics
SAGE
+$6.1M
5
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$5.3M

Top Sells

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$12.7M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$11.3M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$11.1M
4
UTHR icon
United Therapeutics
UTHR
+$9.43M
5
CLDX icon
Celldex Therapeutics
CLDX
+$6.76M

Sector Composition

Rank Sector Weight
1 Healthcare 39.26%
2 Consumer Staples 0%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCUS icon
151
CALL
Arcus Biosciences
RCUS
$3.55B
– –
-23,200
Closed -$588K
RCUS icon
152
PUT
Arcus Biosciences
RCUS
$3.55B
– –
-50,000
Closed -$1.27M
RGLS
153
DELISTED
Regulus Therapeutics
RGLS
– –
-105,341
Closed -$217K
RIGL icon
154
Rigel Pharmaceuticals
RIGL
$681M
– –
-70,277
Closed -$794K
SAGE
155
CALL
DELISTED
Sage Therapeutics
SAGE
– –
-250,000
Closed -$8.07M
TAOX
156
Tao Synergies Inc
TAOX
$24.6M
– –
-4,848
Closed -$614K
TPST icon
157
Tempest Therapeutics
TPST
$13.7M
– –
-4,756
Closed -$132K
UTHR icon
158
United Therapeutics
UTHR
$25.8B
– –
-40,000
Closed -$9.43M
VRDN icon
159
CALL
Viridian Therapeutics
VRDN
$2.09B
– –
-300,000
Closed -$3.47M
VRTX icon
160
Vertex Pharmaceuticals
VRTX
$121B
– –
-40,000
Closed -$11.3M
VSTM icon
161
Verastem
VSTM
$510M
– –
-19,002
Closed -$265K
WVE icon
162
Wave Life Sciences
WVE
$1.09B
– –
-98,039
Closed -$318K
ZLAB icon
163
Zai Lab
ZLAB
$2.06B
– –
-81,843
Closed -$278K
QCLS
164
Q/C Technologies Inc
QCLS
$20.5M
– –
-27
Closed -$176K
RNTX
165
Rein Therapeutics
RNTX
$63.1M
– –
-144,616
Closed -$752K
WHWK
166
Whitehawk Therapeutics
WHWK
$190M
– –
-412,343
Closed -$1.27M
CMRX
167
DELISTED
Chimerix, Inc.
CMRX
– –
-441,203
Closed -$917K
NTBL
168
DELISTED
Notable Labs, Ltd. Ordinary Shares
NTBL
– –
-23,714
Closed -$1.34M
KA
169
DELISTED
Kineta, Inc. Common Stock
KA
– –
-14,913
Closed -$190K
KRTX
170
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
– –
-100,000
Closed -$12.7M
KRTX
171
PUT
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
– –
-100,000
Closed -$12.7M
ICPT
172
CALL
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-350,000
Closed -$4.83M
CYTO
173
DELISTED
Altamira Therapeutics Ltd
CYTO
– –
-188
Closed -$36K
PRDS
174
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
– –
-223,934
Closed -$687K
KDNY
175
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$0 ﹤0.01%
283,464
-48,831
-15% -$979K
4 5 6
7
8

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q3 2022 Portfolio in Review

As of Q3 2022, Ikarian Capital held 180 positions worth $502M, down 8.5% from $548M the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Ikarian Capital withdrew a net $131M in Q3 2022, closing 76 positions and reducing 50 holdings. Its most notable exit was Karuna Therapeutics, Inc. Common Stock, an estimated $12.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 39% of assets, down from 43% a quarter earlier, followed by Consumer Staples and Technology.

Against the trend, Ikarian Capital opened a new position in Prometheus Biosciences, Inc. Common Stock worth $13.6M.

  • Ikarian Capital's largest Q3 2022 buy was Prometheus Biosciences, Inc. Common Stock: 231,181 shares worth $13.6M.
  • Ikarian Capital added most to IVERIC bio, Inc. Common Stock in Q3 2022, an estimated $12.2M increase.
  • Ikarian Capital's biggest Q3 2022 reduction was Alnylam Pharmaceuticals, cutting an estimated $11.1M.
  • Ikarian Capital fully exited Karuna Therapeutics, Inc. Common Stock in Q3 2022, selling an estimated $12.7M.
  • Ikarian Capital's ten largest holdings make up 39% of its $502M portfolio in Q3 2022.
  • Ikarian Capital opened 41 new positions and closed 76 in Q3 2022.
  • Ikarian Capital's portfolio value fell 8.5% quarter-over-quarter to $502M.

Based on Ikarian Capital's 13F filing for Q3 2022, filed 14 Nov 2022.